Has COVID impacted the way you consider using subcutaneous pertuzumab/trastuzumab in treatment of HER2+ breast cancer?  

Only to a small extent since it still requires a visit and infusion center appointment, but could results in less time in the infusion center and reduce the number of individuals in the infusion center at any given time - an important goal of reducing our overall footprint of number of people in our...

Yes.  It has been great to be able to utilize SQ HP so that patient can get in and out of the infusion center much faster.

Its use is very relevant now. When you consider the SARS-CoV-2 pandemic, the option to have a subcutaneous medication available is very favorable for patient care. A main benefit is a shorter infusion time which translates to less time that a patient spends in the treatment chair and less potential ...